Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xelstrym
- Development stage
- Approved
- Lead developer
- Noven Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Xelstrym (dextroamphetamine transdermal system) is a central nervous system (CNS) stimulant patch developed by Noven Therapeutics for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Approved by the FDA in March 2022, it is the first and only transdermal amphetamine patch indicated for both adults and pediatric patients aged 6 years and older. The system provides continuous delivery of dextroamphetamine through the skin, bypassing the gastrointestinal tract and offering a 12-hour duration of effect when worn for 9 hours. Its therapeutic mechanism involves increasing synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic neurons, primarily through interactions with the dopamine transporter (DAT), norepinephrine transporter (NET), and trace amine-associated receptor 1 (TAAR1).
- Brand names
- Xelstrym
- Other names
- dextroamphetamine transdermal systemdextroamphetamine patch
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)TAAR1 (Trace amine-associated receptor 1)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on Xelstrym.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xelstrym.